Fintel reports that on September 9, 2026, Leerink Partners initiated coverage of Amneal Pharmaceuticals (NASDAQGS:AMRX) with a Outperform recommendation. This initiation occurred on September 9, 2026, a day when the stock closed at $17.27, following a pre-action close of $17.05 on September 8, 2026.

Amneal Pharmaceuticals, Inc., based in the United States, operates primarily in the generic and specialty pharmaceutical sectors. Founded in 2002, the company has developed a portfolio that includes generic medicines and specialty pharmaceutical products focusing on central nervous system disorders, endocrinology, and oncology. In a Form 8-K filing dated August 10, 2026, the company reported the completion of transactions contemplated by a Membership Interest Purchase Agreement dated as of April 21, 2026, by and among Amneal Pharmaceuticals, Inc., Kashiv BioSciences, LLC, KB Seller Representative, LLC, and the equityholders of Kashiv named therein. According to the filing, on August 10, 2026, Amneal Pharmaceuticals LLC, a wholly owned subsidiary of Amneal, acted pursuant to the terms and conditions of a previously executed assignment.

Prior to the rating action, the company's stock experienced a price change of -4.37% over one week, relative to a baseline close of $18.06 on September 2, 2026. Over a one-month period, the price change was -4.80% from a baseline close of $18.14 on August 7, 2026. In its latest earnings report on July 30, 2026, Amneal Pharmaceuticals reported an actual EPS of 0.3, compared to an estimated EPS of 0.2259, representing an EPS surprise of +32.80%. The company's actual revenue for the period was $796,197,000,000,000.00, compared to an estimated revenue of $783,570,120,000,000.00.

Separately from Leerink Partners' individual rating, aggregate consensus data as of August 28, 2026, showed a mean target price of $20.85 and a median target price of $21.42, representing an implied change of +20.75% from the previous consensus mean target of $20.44 recorded on August 4, 2026. This represents a consensus target revision of +2.00%. In terms of recommendations, as of September 1, 2026, the consensus recommendation breakdown consisted of 3 strong buy, 7 buy, 1 hold, 0 sell, and 0 strong sell recommendations, totaling 11 recommendations. This breakdown, representing 90.9% positive, 9.1% hold, and 0.0% negative recommendations, remained unchanged from the prior recommendation period as of August 1, 2026. Other recent analyst actions include JP Morgan, which reiterated an Overweight rating on August 26, 2026.

Recent analyst actions

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.